Glaukos Corporation (NYSE: GKOS), a United States-based ophthalmic pharmaceutical and medical technology company, has reported positive topline results from its Phase 4 GLK-101-04 trial evaluating iDose TR (travoprost intracameral implant) alongside cataract surgery in patients with open-angle glaucoma or ocular hypertension. Announced on October 9, 2026, the randomized controlled study met its primary efficacy endpoint, demonstrating a statistically significant additional reduction in intraocular pressure compared with cataract surgery alone after three months.
The trial reported a mean diurnal intraocular pressure reduction of 11.1 mmHg in patients receiving iDose TR with cataract surgery, compared with 7.4 mmHg in the control group. Glaukos reported an incremental treatment effect of 3.6 mmHg, with a p-value below 0.0001, establishing statistical superiority on the prespecified primary endpoint. The findings provide controlled clinical evidence supporting the addition of the sustained-release glaucoma implant during cataract surgery, although the currently disclosed results cover only the first three months.
The development is particularly relevant because iDose TR is already approved by the United States Food and Drug Administration for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The new Phase 4 evidence is therefore not an initial product approval milestone, but an assessment of performance in a commonly encountered surgical setting where glaucoma management and cataract treatment overlap. Its commercial significance will depend on whether the demonstrated pressure reduction can support wider surgeon adoption, sustainable reimbursement and acceptable longer-term outcomes.
What do the GLK-101-04 Phase 4 results reveal about iDose TR efficacy during cataract surgery?
The GLK-101-04 study was designed as a prospective, multicentre, randomized, double-masked, parallel-group clinical trial involving adults with open-angle glaucoma or ocular hypertension undergoing cataract surgery. A total of 149 study eyes were randomized, with 74 assigned to iDose TR administration alongside cataract surgery and 75 assigned to a control procedure involving cataract surgery without the active implant. The study used a sham procedure in the control arm to support masking, reducing the potential for treatment expectations to influence assessments.
The primary efficacy endpoint measured the change from baseline in mean diurnal intraocular pressure at three months. This outcome is clinically relevant because intraocular pressure reduction is an established therapeutic objective in glaucoma management, where controlling elevated pressure can help reduce the risk of progressive optic nerve damage. However, the endpoint measures pressure control rather than directly demonstrating preservation of vision, reduced visual field deterioration or prevention of future glaucoma surgery.
The reported 11.1 mmHg reduction in the iDose TR group compared with 7.4 mmHg in the control group indicates that the implant provided additional pressure reduction beyond the effect associated with cataract surgery alone. Glaukos reported a 3.6 mmHg between-group treatment effect, with statistical significance at p<0.0001. The reported treatment difference is consistent with the rounded group reductions, and its magnitude is potentially clinically relevant, although the implications for individual patients depend on baseline pressure, disease severity and the pressure target established by their treating ophthalmologist.
Glaukos also reported statistically significant superiority across all prespecified secondary responder analyses. These findings suggest that the primary result was supported by additional assessments of treatment response, although the announcement did not provide the individual responder thresholds, percentages, confidence intervals or detailed statistical analyses. The topline disclosure therefore supports a positive efficacy interpretation but does not yet permit an independent assessment of the full distribution of treatment responses.
Why does the additional 3.6 mmHg pressure reduction matter for patients with glaucoma and cataracts?
Cataracts and glaucoma frequently coexist, particularly among older patients, creating situations in which ophthalmologists must manage both visual impairment caused by lens opacity and the longer-term risk associated with elevated intraocular pressure. Cataract surgery can itself lower intraocular pressure in some patients, but the magnitude and durability of that effect vary according to ocular characteristics and underlying disease. Consequently, removing a cataract does not automatically eliminate the need for ongoing glaucoma treatment.
The GLK-101-04 findings demonstrate the importance of using an active surgical comparison rather than evaluating pressure reduction only against untreated baseline measurements. Cataract surgery alone produced a substantial 7.4 mmHg mean reduction in the control arm, meaning that the additional benefit associated with iDose TR must be assessed against an intervention that already affects pressure. The statistically significant between-group difference supports the contribution of the implant within the studied population, without implying that every patient undergoing cataract surgery would obtain the same incremental reduction.
The therapeutic rationale is also different from that of conventional topical glaucoma medications. iDose TR contains 75 micrograms of travoprost, a prostaglandin analogue, delivered through an intracameral implant anchored within the eye’s drainage-angle region. The system is designed to release medication continuously, potentially reducing the need for daily topical administration during periods when the implant provides adequate pressure control.
That approach addresses an important limitation of long-term glaucoma treatment, namely the difficulty some patients experience maintaining prescribed eye-drop regimens over many years. Difficulties involving medication administration, dosing schedules, ocular surface symptoms and treatment persistence can affect real-world management. Nevertheless, the Phase 4 announcement did not establish that the combination reduced medication burden by a specified amount, improved adherence-related outcomes or prevented visual deterioration compared with cataract surgery alone.
How strong is the safety evidence for combining iDose TR with cataract surgery?
Glaukos reported a favourable safety profile through the three-month evaluation period, with no treatment-related adverse events involving corneal endothelial cell loss or cystoid macular edema and no serious corneal adverse events. These findings are encouraging for an ophthalmic intervention involving intracameral drug delivery during surgery, particularly because corneal health and postoperative macular complications are important considerations in cataract patients. The reported observations should nevertheless be interpreted within the limitations of a 149-eye study and its relatively short disclosed follow-up.
The corneal endothelium is particularly relevant because it helps maintain corneal transparency, and meaningful endothelial cell loss can compromise visual outcomes. Cystoid macular edema is another clinically important concern following ocular surgery, especially in patients with additional risk factors. The absence of the specified treatment-related events during the disclosed assessment period is reassuring, but it does not establish that these complications cannot occur or that longer-term risk is negligible.
The current United States prescribing information for iDose TR includes warnings concerning corneal endothelial cell loss, macular edema, intraocular inflammation, implant dislocation and other ocular complications. It also identifies contraindications involving active or suspected ocular infections, corneal endothelial dystrophy, prior corneal transplantation and hypersensitivity to the product’s components. These established precautions remain applicable despite the positive Phase 4 results, and the company has not yet provided a complete adverse-event table for the cataract combination study.
A further consideration is that cataract surgery and intracameral implantation each involve manipulation of ocular structures, making postoperative safety assessment more complex than evaluation of a topical medicine alone. Larger datasets and longer follow-up would be valuable for characterising uncommon complications, implant positioning and changes in endothelial cell density. The current topline results support acceptable short-term tolerability within the study population but do not replace the need for continued safety surveillance.
Does the Phase 4 success change the FDA-approved status or long-term use of iDose TR?
The United States Food and Drug Administration approved iDose TR in December 2023 for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Glaukos began commercial launch activities in 2024, positioning the implant as a sustained-release alternative to repeated topical glaucoma medication administration. The Phase 4 GLK-101-04 trial evaluates an additional clinical treatment setting for an already authorised product rather than establishing a new initial marketing authorisation.
An important subsequent regulatory development occurred in January 2026, when the FDA approved updated prescribing information permitting repeat administration in appropriately selected patients. The revised label includes specific considerations relating to corneal endothelial cell density, previous adverse events and the condition of the treated eye. It also states that readministration more than once annually is not recommended, meaning repeat treatment remains subject to defined safety and clinical requirements.
That regulatory context matters because the Phase 4 results are being generated for a product whose permitted administration practices have evolved since its original approval. The combination trial may provide additional evidence for clinicians considering treatment alongside cataract surgery, but its success does not automatically establish a new regulatory indication or alter every aspect of the existing label. Any subsequent prescribing information changes would require the relevant regulatory process and supporting evidence.
The product’s longer-term effectiveness also needs to be distinguished from the three-month endpoint in the latest trial. Glaukos has previously generated longer-duration evidence for iDose TR in its broader glaucoma development programme, including pivotal studies comparing the implant with topical timolol treatment. Those studies support the product’s established development and regulatory history, but they do not independently demonstrate that the pressure reduction observed in GLK-101-04 will persist for the same duration when implantation is combined with cataract surgery.
How could the findings influence cataract surgeons and the interventional glaucoma market?
The commercial opportunity centres on integrating sustained-release pharmacological treatment into the existing cataract surgery pathway for appropriately selected patients with glaucoma or ocular hypertension. Combining interventions could be attractive when physicians determine that patients need cataract removal and additional pressure control, particularly if the treatment reduces subsequent reliance on topical medications. However, adoption will depend on how the implant fits into surgical planning, physician training and postoperative monitoring.
iDose TR implantation requires visualisation of the anterior chamber angle and secure placement of the implant in scleral tissue. The prescribing information also contains procedural instructions concerning pupil size, angle visualisation and positioning, making surgical sequencing important when implantation is performed in conjunction with cataract extraction. Cataract procedures ordinarily involve pharmacological pupil dilation, so integrating the two interventions requires attention to their different procedural requirements rather than assuming that combining them is operationally straightforward.
The findings also strengthen the evidence available for discussing iDose TR alongside other interventional glaucoma options. Glaukos already markets micro-invasive glaucoma surgery products through its iStent portfolio, while competing approaches include trabecular bypass devices, other minimally invasive procedures, laser treatment and conventional medication strategies. iDose TR differs from procedures intended primarily to improve aqueous outflow mechanically because it delivers a sustained-release pharmaceutical agent within the eye.
The GLK-101-04 study was not a head-to-head comparison against competing minimally invasive glaucoma surgery devices or alternative sustained-release treatments. Its findings therefore cannot establish that iDose TR provides superior pressure control, safety or long-term value compared with those options. Direct comparative evidence, patient selection criteria and the practical economics of different treatment pathways will remain important when surgeons decide how to manage glaucoma during cataract procedures.
Could reimbursement and surgical economics determine the pace of iDose TR adoption?
Clinical efficacy is only one component of adoption for procedure-based ophthalmic pharmaceuticals, particularly in the United States healthcare system. Hospitals, ambulatory surgery centres and ophthalmology practices must evaluate the acquisition cost of the implant, reimbursement for the pharmaceutical component, procedural payment and the financial implications of combining services. A clinically favourable outcome does not necessarily translate into widespread use if payment arrangements create substantial uncertainty for providers.
iDose TR has an established product-specific Healthcare Common Procedure Coding System code, J7355, while procedural billing guidance identifies code 0660T for implantation of an anterior segment intraocular nonbiodegradable drug-eluting system. These coding mechanisms facilitate claims submission but do not guarantee payment for every patient, payer or setting. Coverage decisions and reimbursement rules can differ between traditional Medicare, Medicare Advantage and commercial insurers.
The economics of implantation during cataract surgery may also differ from those of a standalone glaucoma intervention. Combining procedures can affect operating-room time, facility payment arrangements and professional reimbursement, creating practical considerations for surgeons and healthcare organisations. The Phase 4 study did not disclose comparative treatment costs, surgical time requirements or formal health economic outcomes.
A broader commercial assessment would require information on whether combined treatment reduces subsequent prescription medication use, additional glaucoma procedures or other healthcare resource requirements. Any potential savings would need to be weighed against product acquisition, administration and follow-up costs. Until those outcomes are measured, the clinical efficacy result provides a stronger basis for evaluating treatment utility than for projecting healthcare cost savings.
What do the latest Glaukos financial results and share-price movements indicate?
The Phase 4 announcement arrives during a period of substantial commercial growth for Glaukos Corporation, driven partly by increasing adoption of iDose TR. In the second quarter of 2026, the company reported net sales of $185.6 million, representing a 50% increase from the comparable period in 2025. Its United States glaucoma business generated approximately $118.5 million in quarterly revenue, supported by growing contributions from its interventional glaucoma portfolio.
iDose TR alone generated approximately $74 million in second-quarter sales, representing nearly 40% of Glaukos Corporation’s consolidated quarterly revenue. This indicates that the sustained-release treatment has become a commercially important product rather than remaining an early-stage technology with limited market exposure. Glaukos also increased its full-year 2026 sales guidance to $680 million to $700 million in July, citing stronger commercial momentum across its portfolio.
The financial significance of the Phase 4 results lies primarily in their potential to support continued utilisation and broaden physician confidence in an already marketed product. The announcement does not include additional revenue guidance, a projected number of combined cataract procedures or a quantified expansion in the addressable market. Any future sales benefit will depend on incremental treatment volumes, reimbursement access and the ability of trained surgeons to incorporate the implant into routine clinical practice.
Glaukos shares closed at $165.69 on October 9, 2026, gaining approximately 2.7% during the trading session following the Phase 4 announcement. The positive trading session followed a 6.3% decline on October 8, illustrating the volatility surrounding the company during a period that also included other clinical and business developments. The share-price recovery coincided with the latest trial disclosure, but the available evidence does not establish that the Phase 4 results alone caused the movement.
Investor attention is likely to remain focused on the commercial trajectory of iDose TR, particularly because it represents a substantial component of United States glaucoma revenue. Growth in procedural volume and wider surgeon participation could support the product’s contribution, while changes in payer coverage, reimbursement policy or clinical adoption could affect its trajectory. Glaukos is scheduled to report third-quarter 2026 financial results on October 28, providing another opportunity to assess overall commercial performance.
What evidence will determine whether the Phase 4 results support wider clinical adoption?
The immediate priority will be obtaining a fuller presentation of GLK-101-04, including detailed responder results, baseline characteristics, confidence intervals and the complete adverse-event profile. The topline announcement establishes a statistically significant primary endpoint result, but additional information will help ophthalmologists assess the consistency of benefit across patients with differing baseline pressures and glaucoma characteristics. Data on postoperative medications and subsequent interventions would also clarify whether the incremental pressure reduction produces measurable changes in treatment requirements.
Longer-term follow-up will be particularly valuable because glaucoma requires sustained pressure management rather than short-term control alone. A three-month improvement can demonstrate early therapeutic activity, but it cannot establish how consistently the benefit persists over one or several years in eyes undergoing combined treatment. Monitoring corneal endothelial health, implant position, inflammation and any subsequent need for additional pressure-lowering therapy will remain relevant to the clinical assessment.
The results nevertheless provide a meaningful addition to the evidence supporting iDose TR. A randomized comparison against cataract surgery alone addresses a practical clinical question and demonstrates that the implant can provide additional pressure reduction within the studied treatment setting. The next measure of success will be whether the initial efficacy advantage is accompanied by durable control, manageable safety outcomes and implementation pathways that make the combined procedure suitable for routine ophthalmic practice.
For Glaukos Corporation, the study strengthens an established commercial product at a time when its United States glaucoma business is expanding rapidly. The company’s challenge is no longer limited to proving that sustained intracameral travoprost can lower intraocular pressure, but increasingly involves demonstrating where the treatment offers the greatest clinical value among existing glaucoma interventions. Continued evidence generation, reimbursement access and sustained surgeon adoption will determine how far the positive GLK-101-04 findings can extend the role of iDose TR in cataract-associated glaucoma management.
